Efficacy of switching to entecavir monotherapy in Japanese lamivudine-pretreated patients

Journal of Gastroenterology and Hepatology (Australia)

Volumn 25, Issue 5, 2010, Pages 892-898

  Suzuki, Fumitaka ^a   Akuta, Norio ^a   Suzuki, Yoshiyuki ^a   Yatsuji, Hiromi ^a   Sezaki, Hitomi ^a   Arase, Yasuji ^a   Hirakawa, Miharu ^a   Kawamura, Yusuke ^a   Hosaka, Tetsuya ^a   Kobayashi, Masahiro ^a   Saitoh, Satoshi ^a   Ikeda, Kenji ^a   Kobayashi, Mariko ^a   Watahiki, Sachiyo ^a   Kumada, Hiromitsu ^a  

^a TORANOMON HOSPITAL   (Japan)

Author keywords

Entecavir; Hepatitis B virus; Lamivudine; Viral resistance

Indexed keywords

ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ENTECAVIR; LAMIVUDINE; VIRUS DNA; ANTIVIRUS AGENT; BIOLOGICAL MARKER; GUANINE;

ADD ON THERAPY; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHRONIC HEPATITIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT DURATION; VIRUS INHIBITION; VIRUS LOAD; FOLLOW UP; JAPANESE (PEOPLE); VIRUS RESISTANCE; ANALOGS AND DERIVATIVES; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD; CHI SQUARE DISTRIBUTION; ETHNOLOGY; GENETICS; HEPATITIS B, CHRONIC; JAPAN; MIDDLE AGED; MUTATION; RISK; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL; TIME; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL MARKERS; CHI-SQUARE DISTRIBUTION; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; GUANINE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; JAPAN; LAMIVUDINE; LOGISTIC MODELS; MALE; MIDDLE AGED; MUTATION; ODDS RATIO; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 77951736627     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2009.06161.x     Document Type: Article

References (33)

1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J. Viral Hepat. 2004 11 : 97 107.
2. Liaw Y-F, Leung N, Kao J-H et al. Asian-Pacifc consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol. Int. 2008 2 : 263 283.
3. Chen CJ, Yang HI, Su J et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006 295 : 65 73.
4. Iloeje U, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting liver cirrhosis risk based on the level of circulating hepatitis B viral load. J. Gastroenterol. 2006 678 686.
5. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007 45 : 507 539.
6. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J. Hepatol. 2009 50 : 227 242.
7. Locarnini S, Mason WS. Cellular and virological mechanisms of HBV drug resistance. J. Hepatol. 2006 44 : 422 431.
8. Lok AS, Zoulim F, Locarnini S et al. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology 2007 46 : 254 265.
9. Suzuki F, Tsubota A, Arase Y et al. Efficacy of lamivudine therapy and factors associated with emergence of resistance in chronic hepatitis B virus infection in Japan. Intervirology 2003 46 : 182 189.
10. Chang TT, Gish RG, de Man R et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 2006 354 : 1001 1010.
11. Gish RG, Lok AS, Chang TT et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007 133 : 1437 1444.
12. Lai CL, Shouval D, Lok AS et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 2006 354 : 1011 1020.
13. Ren FY, Piao DM, Piao XX. A one-year trial of entecavir treatment in patients with HBeAg-positive chronic hepatitis B. World J. Gastroenterol. 2007 13 : 4264 4267.
14. Schiff E, Simsek H, Lee WM et al. Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis. Am. J. Gastroenterol. 2008 103 : 1 8.
15. Colonno RJ, Rose R, Baldick CJ et al. Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology 2006 44 : 1656 1665.
16. Tenney DJ, Rose RE, Baldick CJ, Pokornowski K, Eggers BJ. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. Hepatology 2009 49 : 1503 1514.
17. Baldick CJ, Eggers BJ, Fang J et al. Hepatitis B virus quasispecies susceptibility to entecavir confirms the relationship between genotypic resistance and patient virologic response. J. Hepatol. 2008 48 : 895 902.
18. Tenney DJ, Rose RE, Baldick CJ et al. Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob. Agents Chemother. 2007 51 : 902 911.
19. Tenney DJ, Levine SM, Rose RE et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob. Agents Chemother. 2004 48 : 3498 3507.
20. Nagasaki F, Niitsuma H, Ueno Y et al. The high incidence of the emergence of entecavir-resistant mutants among patients infected with lamivudine-resistant hepatitis B virus. Tohoku J. Exp. Med. 2007 213 : 181 186.
21. Villet S, Ollivet A, Pichoud C et al. Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient. J. Hepatol. 2007 46 : 531 538.
22. Sherman M, Yurdaydin C, Simsek H et al. Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks. Hepatology 2008 48 : 99 108.
23. Sherman M, Yurdaydin C, Sollano J et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 2006 130 : 2039 2049. (Pubitemid 43816960)
24. Suzuki F, Toyoda J, Katano Y et al. Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: randomized controlled trial in Japanese patients. J. Gastroenterol. Hepatol. 2008 23 : 1320 1326.
25. Matsuyama K, Hayashi K, Miura T. The quantitative assay for HBV-DNA and the detection of HBV-DNA point mutation by polymerase chain reaction - 'AMPLICOR HBV MONITOR Test' and 'HBV pre Core/Core Promoter Mutation Detection kit. Kan Tan Sui 2000 41 : 59 71.
26. Kobayashi S, Shimada K, Suzuki H, Tanikawa K, Sata M. Development of a new method for detecting a mutation in the gene encoding hepatitis B virus reverse transcriptase active site (YMDD motif). Hepatol. Res. 2000 17 : 31 42.
27. Suzuki F, Kumada H, Nakamura H. Changes in viral loads of lamivudine-resistant mutants and evolution of HBV sequences during adefovir dipivoxil therapy. J. Med. Virol. 2006 78 : 1025 1034.
28. Kumada H. Scientific Research Grant of Ministry of Health, Labour and Welfare. Research of hepatitis overcome urgent strategy. Research report of the standardization of viral hepatitis treatment including liver cirrhosis (Japanese version). 2009.
29. Chang TT, Gish RG, Hadziyannis SJ et al. A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients. Gastroenterology 2005 129 : 1198 1209.
30. Kobashi H, Fujioka S-I, Kumada H, Yokosuka O, Hayashi N, Suzuki K. Emergence of hepatitis B virus gene mutation related to entecavir-resistance in chronic hepatitis B patients participated in the phase 2 clinical studies of entecavir in Japan. Hepatology 2007 46 (Suppl. 1 666A.
31. Lai CL, Gane E, Liaw YF et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. Hepatology 2006 44 : 222A.
32. Yuen MF, Fong DY, Wong DK, Yuen JC, Fung J, Lai CL. Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response. Hepatology 2007 46 : 1695 1703.
33. Takahashi K, Akahane Y, Hino K, Ohta Y, Mishiro S. Hepatitis B virus genomic sequence in the circulation of hepatocellular carcinoma patients: comparative analysis of 40 full-length isolates. Arch Virol 1998 143 : 2312 2326.